May 14, 2025 08:40 ET – VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial – – Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 – ROCKVILLE, Md., May 14, 2025 […]
May 09, 2025 16:46 ET ROCKVILLE, Maryland, May 09, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy el cierre de su oferta pública de «mejores
Theriva Biologics anuncia el cierre de una oferta pública de 7,5 millones de dólares Read More »
May 08, 2025 07:05 ET ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy el precio de su oferta pública de «mejores esfuerzos razonables» para la
Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares Read More »
May 08, 2025 16:30 ET ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of
Theriva Biologics Announces Closing of $7.5 Million Public Offering Read More »
May 07, 2025 09:17 ET ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase
Theriva Biologics Announces Pricing of $7.5 Million Public Offering Read More »
May 07, 2025 07:00 ET – Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC – – VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint – – Greater differences
May 07, 2025 18:06 ET – Los pacientes tratados con VCN-01 (zabilugene almadenorepvec) más quimioterapia estándar con gemcitabina/nab-paclitaxel presentaron un aumento de la supervivencia global, la supervivencia libre de progresión y la duración de la respuesta en comparación con los pacientes tratados con gemcitabina/nab-paclitaxel estándar – – VCN-01 presentó una tolerancia adecuada, con acontecimientos adversos
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) April 10, 2025 08:00 ET ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat
En el Congreso de la European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), se presentarán datos provisionales ciegos de seguridad y farmacocinética April 10, 2025 15:23 ET ROCKVILLE, Maryland, April 10, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa diversificada de fase clínica que desarrolla terapias
The independent data monitoring committee (IDMC) considered VCN-01 to be well tolerated in metastatic PDAC patients treated with standard-of-care chemotherapy gemcitabine/nab-paclitaxel March 31, 2025 08:00 ET ROCKVILLE, Md., March 31, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of
